Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in the ...
Cantor Fitzgerald raised the firm’s price target on Tesla (TSLA) to $425 from $365 and keeps a Neutral rating on the shares. Tesla’s adjusted ...
Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested ...
Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...
Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish ...
Donald Trump's commerce secretary nominee said Wednesday that he favors "across-the-board" tariffs and a country-based ...
Cantor Fitzgerald CEO and Commerce Secretary nominee Howard Lutnick became visibly emotional at his confirmation hearing ...
For exclusive news and updates, subscribe to our Survivor Newsletter: It’s been nearly 10 years since Michele Fitzgerald was crowned the winner of Survivor Season 32, but she’s still haunted ...
We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a look at where Varonis Systems, Inc. (NASDAQ:VRNS) stands against the ...
Cantor Fitzgerald analyst Deepak Mathivanan downgraded Sabre (SABR) to Neutral from Overweight with a price target of $4, down from $5, after assuming coverage of the name. Cantor expects fiscal ...